Study of radiation and hormone therapy for high-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at combining stereotactic body radiation therapy (a precise type of radiation) with hormone therapy for men with high-risk prostate cancer that hasn't spread. The goal is to see how well this treatment works with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a confirmed diagnosis of prostate cancer.
- Your cancer is considered high-risk based on standard guidelines (for example, a high PSA level or a higher grade group).
- A PET scan shows your cancer hasn't spread to lymph nodes or other organs.
- You have a good performance status (able to take care of yourself).
- Your prostate is not too large (less than about 100 cc) and your urinary symptoms are not severe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a higher dose of radiation therapy (called SBRT) can safely and effectively treat high-risk prostate cancer that hasn't spread. It's for men who have not yet been treated for their cancer.
This Phase 3 trial compares two treatment approaches: stereotactic radiation therapy by itself versus the same radiation plus hormone therapy (ADT). It aims to see which plan works better for men with higher-risk prostate cancer without spread to lymph nodes or distant sites.
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
This trial tests whether combining standard hormone therapy and radiation with a special targeted radiation (PSMA-targeted radiotherapy) is safe and effective for men with high-risk prostate cancer that hasn't spread outside the pelvis.
This trial studies a combination of two radiation types—high-dose-rate brachytherapy and stereotactic body radiotherapy—to treat certain intermediate- to high-risk prostate cancers. It may help by aiming radiation closely at the prostate while also targeting the cancer from outside the body.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
Hear when a new High Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.